The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US

[1]  Ron Goeree,et al.  Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  D. Witt,et al.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.

[3]  L. Kalra,et al.  Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated? , 2005, Stroke.

[4]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[5]  W. Lim,et al.  People Aged Over 75 in Atrial Fibrillation on Warfarin: The Rate of Major Hemorrhage and Stroke in More Than 500 Patient‐Years of Follow‐Up , 2005, Journal of the American Geriatrics Society.

[6]  J. Menzin,et al.  Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study , 2005, The Annals of pharmacotherapy.

[7]  J. Hambleton.  Home Monitoring of Anticoagulation , 2003, Journal of Thrombosis and Thrombolysis.

[8]  R. Greenlee,et al.  Recent progress in the epidemiology of atrial fibrillation , 2005, Current opinion in cardiology.

[9]  D K Owens,et al.  The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. , 1996, Archives of internal medicine.

[10]  Yin Zhao-fang.  Antithrombotic therapy of warfarin and aspirin in nonvalvular atrial fibrillation , 2008 .

[11]  D. Witter,et al.  Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. , 2000, Archives of internal medicine.

[12]  D. Desilvey.  Clinical trials: advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. , 2005, The American journal of geriatric cardiology.

[13]  J. Lafata,et al.  The cost-effectiveness of different management strategies for patients on chronic warfarin therapy , 2007, Journal of General Internal Medicine.

[14]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.

[15]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[16]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.

[17]  G. Lip.  ABC of atrial fibrillation , 1996 .

[18]  M G Amato,et al.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.

[19]  E. Benjamin,et al.  Epidemiology and significance of atrial fibrillation. , 1999, The American journal of cardiology.

[20]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[21]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[22]  R. Kronmal,et al.  Lessons from the Stroke Prevention in Atrial Fibrillation Trials , 2003, Annals of Internal Medicine.

[23]  J D Graham,et al.  Modeling for health care and other policy decisions: uses, roles, and validity. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  S. Tandy,et al.  Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital , 2004, Heart.

[25]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[26]  Jeremy N Ruskin,et al.  National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. , 2004, Archives of internal medicine.

[27]  M. Feinleib.  National Center for Health Statistics (NCHS) , 2005 .

[28]  X. Bonfill,et al.  Comparing Self-Management of Oral Anticoagulant Therapy with Clinic Management , 2005, Annals of Internal Medicine.

[29]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[30]  L. Kalra,et al.  The Economic Burden of Stroke in the United Kingdom , 2012, PharmacoEconomics.

[31]  R. Glávits,et al.  Epidemiology and significance of Q fever in Hungary. , 1987, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

[32]  J. Seward,et al.  Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study , 2005, Stroke.

[33]  G. Samsa,et al.  Which Approach to Anticoagulation Management is Best?: Illustration of an Interactive Mathematical Model to Support Informed Decision Making , 2002, Journal of Thrombosis and Thrombolysis.

[34]  J. Tu,et al.  The high risk of stroke immediately after transient ischemic attack , 2004, Neurology.

[35]  Margaret C Fang,et al.  Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation , 2004, Annals of Internal Medicine.

[36]  B. Gage,et al.  The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life , 1996 .

[37]  J. Ansell.  Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High-Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management , 2003, Seminars in vascular medicine.

[38]  J. Caro,et al.  Long Term Cost-of-Illness in Stroke , 2012, PharmacoEconomics.

[39]  J. Ansell,et al.  Barriers to Patient Self‐Testing of Prothrombin Time: National Survey of Anticoagulation Practitioners , 2005, Pharmacotherapy.

[40]  Vahram Ghushchyan,et al.  A National Catalog of Preference-Based Scores for Chronic Conditions in the United States , 2005, Medical care.

[41]  Rajul A. Patel,et al.  Reduction in Warfarin Adverse Events Requiring Patient Hospitalization After Implementation of a Pharmacist‐Managed Anticoagulation Service , 2005, Pharmacotherapy.

[42]  G. Samsa,et al.  Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. , 2002, The American journal of medicine.

[43]  J. Caro,et al.  Stroke treatment economic model (STEM): predicting long-term costs from functional status. , 1999, Stroke.

[44]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[45]  M. Hennerici,et al.  Transient Ischemic Attacks Are More Than “Ministrokes” , 2004, Stroke.

[46]  MichaelHennerici,et al.  Transient Ischemic Attacks Are More Than “Ministrokes” , 2004 .

[47]  J. Caro.  An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. , 2004, The American journal of managed care.

[48]  S. Iliceto,et al.  Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study , 2006, Journal of Thrombosis and Thrombolysis.

[49]  D. Beevers,et al.  ABC of Atrial Fibrillation: HISTORY, EPIDEMIOLOGY, AND IMPORTANCE OF ATRIAL FIBRILLATION , 1995, BMJ.

[50]  Patrick W. Sullivan,et al.  Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[51]  Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin , 2006, Heart.

[52]  P. Koudstaal,et al.  Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial , 2004, Stroke.